LAGUNA HILLS, Calif., Sept. 4 CODA Genomics, Inc., apioneer in applying its namesake technology, (Computational Optimized DNAAssembly) towards the manufacture of synthetic genes and other DNA fragments,announced today that the US Patent and Trademark Office has issued US Patent7,262,031 to its two founding scientists, University of California, Irvine(UCI) professors, Richard H. Lathrop and G. Wesley Hatfield. The technologywas developed under a prestigious Information Technology Research grant fromthe National Science Foundation jointly in the School of Medicine and theDonald Bren School of Information and Computer Sciences at UCI. The Companyhas licensed this patent exclusively from the UCI's Office of TechnologyAssessment (OTA).
US Patent 7,262,031 entitled, "Method for Producing a Synthetic Gene orOther DNA Sequence," teaches how to use a global (across all possible correctand incorrect gene assemblies) optimization method for the choice of DNA codeto make a given protein. Properly chosen DNA enables the thermodynamicallycontrolled self-assembly of only the desired DNA product(s). The syntheticgene is simultaneously optimized for many other parameters that affect thesuccessful use of the gene to make protein efficiently in any desiredbiological system.
Dr. Robert J Molinari, Ph.D., CODA's CEO said, "This broad protection ofCODA's breakthrough technology will allow the company to aggressively marketits high-yielding Hot-RodTM genes, and other optimized gene variant sets. Forthe customer, it allows a scaleable way to test a large number of gene andprotein variants for desirable properties."
David Schetter, assistant Vice-chancellor, Research and TechnologyAlliances, at UCI adds "CODA has been one of UCI's first, successful examplesof OTA's "Virtual Incubation" model where early stage technology is licensedto a start-up company and the technology is incubated in the University by wayof a series of standard agreements for research, technology development andaccess to UCI's facilities and equipment. All of these agreements arenegotiated at arm's length and meet the university's standards for proper useof university facilities and mitigation of conflicts of interest. As a result,the University gains additional resources and a role in ensuring the successof the technology while the company does not incur premature and expensivespin-out costs. Additionally, with more well developed and proven technology,the company is better able to raise required capital to move to itsnon-virtual stage."
About CODA Genomics, Inc.
CODA Genomics, Inc. is a protein Translation Engineering company focusedon proprietary patented approaches to express proteins in a variety oforganisms. This unique technology enables synthetic biology to solve manyprotein expression problems. For more CODA information, visithttp://www.codagenomics.com.
SOURCE CODA Genomics, Inc.